Investor's Business Daily on MSN
The gene-editing news that sent beleaguered Intellia Therapeutics stock up
Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results